Alternative lengthening of telomeres in mammalian cells

被引:519
作者
Henson, JD [1 ]
Neumann, AA [1 ]
Yeager, TR [1 ]
Reddel, RR [1 ]
机构
[1] Childrens Med Res Inst, Sydney, NSW 2145, Australia
关键词
telomere; alternative lengthening of telomeres; ALT-associated PML bodies; recombination; immortalization; cancer;
D O I
10.1038/sj.onc.1205058
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Some immortalized mammalian cell lines and tumors maintain or increase the overall length of their telomeres in the absence of telomerase activity by one or more mechanisms referred to as alternative lengthening of telomeres (ALT). Characteristics of human ALT cells include great heterogeneity of telomere size (ranging from undetectable to abnormally long) within individual cells, and ALT-associated PML bodies (APBs) that contain extrachromosomal telomeric DNA, telomere-specific binding proteins, and proteins involved in DNA recombination and replication. Activation of ALT during immortalization involves recessive mutations in genes that are as yet unidentified. Repressors of ALT activity are present in normal cells and some telomerase-positive cells. Telomere length dynamics in ALT cells suggest a recombinational mechanism. Inter-telomeric copying occurs, consistent with a mechanism in which single-stranded DNA at one telomere terminus invades another telomere and uses it as a copy template resulting in net increase in telomeric sequence. It is possible that t-loops, linear and/or circular extrachromosomal telomeric DNA, and the proteins found in APBs, may be involved in the mechanism. ALT and telomerase activity can co-exist within cultured cells, and within tumors. The existence of ALT adds some complexity to proposed uses of telomere-related parameters in cancer diagnosis and prognosis, and poses challenges for the design of anticancer therapeutics designed to inhibit telomere maintenance.
引用
收藏
页码:598 / 610
页数:13
相关论文
共 152 条
  • [61] Coordinated response of mammalian Rad51 and Rad52 to DNA damage
    Liu, YL
    Maizels, N
    [J]. EMBO REPORTS, 2000, 1 (01) : 85 - 90
  • [62] Telomerase activity in thyroid malignancy
    Lo, CY
    Lam, KY
    Chan, KT
    Luk, JM
    [J]. THYROID, 1999, 9 (12) : 1215 - 1220
  • [63] Lombard DB, 2000, CANCER RES, V60, P2331
  • [64] Structure, subnuclear distribution, and nuclear matrix association of the mammalian telomeric complex
    Luderus, ME
    vanSteensel, B
    Chong, L
    Sibon, OCM
    Cremers, FFM
    deLange, T
    [J]. JOURNAL OF CELL BIOLOGY, 1996, 135 (04) : 867 - 881
  • [65] AN ALTERNATIVE PATHWAY FOR YEAST TELOMERE MAINTENANCE RESCUES EST1- SENESCENCE
    LUNDBLAD, V
    BLACKBURN, EH
    [J]. CELL, 1993, 73 (02) : 347 - 360
  • [66] Accumulation of short telomeres in human fibroblasts prior to replicative senescence
    Martens, UM
    Chavez, EA
    Poon, SSS
    Schmoor, C
    Landsdorp, PM
    [J]. EXPERIMENTAL CELL RESEARCH, 2000, 256 (01) : 291 - 299
  • [67] Telomerase activity and telomere length in thyroid neoplasia: biological and clinical implications
    Matthews, P
    Jones, CJ
    Skinner, J
    Haughton, M
    de Micco, C
    Wynford-Thomas, D
    [J]. JOURNAL OF PATHOLOGY, 2001, 194 (02) : 183 - 193
  • [68] Properties and assembly mechanisms of ND10, PML bodies, or PODs
    Maul, GG
    Negorev, D
    Bell, P
    Ishov, AM
    [J]. JOURNAL OF STRUCTURAL BIOLOGY, 2000, 129 (2-3) : 278 - 287
  • [69] Cap-prevented recombination between terminal telomeric repeat arrays (telomere CPR) maintains telomeres in Kluyveromyces lactis lacking telomerase
    McEachern, MJ
    Blackburn, EH
    [J]. GENES & DEVELOPMENT, 1996, 10 (14) : 1822 - 1834
  • [70] MCEACHERN MJ, 2001, IN PRESS TELOMERES T